- Home
- NSIT vs HCM Comparison
NSIT vs HCM Comparison
Compare NSIT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSIT | HCM |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | NSIT | HCM |
|---|---|---|
| Price | $67.13 | $15.34 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 4 | 1 |
| Target Price | ★ $118.75 | $13.75 |
| AVG Volume (30 Days) | ★ 369.3K | 30.6K |
| Earning Date | 04-30-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.86 | N/A |
| Revenue | ★ $8,247,180,000.00 | N/A |
| Revenue This Year | $3.79 | $28.37 |
| Revenue Next Year | $2.16 | $17.50 |
| P/E Ratio | $13.84 | ★ $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $63.62 | $11.51 |
| 52 Week High | $148.36 | $19.50 |
Technical Indicators
Market Signals| Indicator | NSIT | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 35.64 | 64.17 |
| Support Level | N/A | $14.62 |
| Resistance Level | $87.42 | $15.49 |
| Average True Range (ATR) | 3.81 | 0.41 |
| MACD | -0.48 | 0.16 |
| Stochastic Oscillator | 16.77 | 79.74 |
Price Performance
Historical ComparisonAbout NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.